Today: 27 February 2026
Subscribe
Browse Category

NASDAQ:ADPT 19 August 2025 - 6 February 2026

Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

Adaptive Biotechnologies (ADPT) stock jumps as biotech gains; SEC filing flags insider sale

Adaptive Biotechnologies shares climbed 6.5% to $17.15 by midday Wednesday, outpacing broader market gains. Biotech ETFs rose about 2.5%. A Form 4 showed Chief People Officer Francis Lo sold 3,125 shares on Jan. 2 under a prearranged 10b5-1 plan, after exercising options. The company is set to present at the J.P. Morgan Healthcare Conference on Jan. 12.
7 January 2026
··
Pfizer Stock After Hours (PFE) on Dec. 15, 2025: What Moved Shares Today—and What to Watch Before Tuesday’s Open

Pfizer Stock After Hours (PFE) on Dec. 15, 2025: What Moved Shares Today—and What to Watch Before Tuesday’s Open

Pfizer shares closed Monday at $26.43, up 2.24%, then slipped to $26.34 after hours. Investors are awaiting Tuesday’s analyst call, where management is set to outline 2026 guidance. The company announced a new autoimmune research deal with Adaptive Biotechnologies, worth up to $890 million in milestones. Trading volume was about 60 million shares, below average.
16 December 2025
···
Biggest Stock Losers Today (December 5, 2025): Parsons, Adaptive Biotechnologies, SentinelOne, SoFi and More Slide Despite Calm Markets

Biggest Stock Losers Today (December 5, 2025): Parsons, Adaptive Biotechnologies, SentinelOne, SoFi and More Slide Despite Calm Markets

The S&P 500 closed at 6,870.40, up 0.19% Friday, while Bitcoin fell 3% to just under $89,300. Parsons plunged 21% after losing a key FAA contract; other steep U.S. decliners included Adaptive Biotechnologies, SentinelOne, and several Brazilian financials. Brazil’s Bovespa index dropped 4% after Jair Bolsonaro endorsed his son for president, sending the real down 3%.
6 December 2025
··········
Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Biotech Breakthroughs, Pharma Power Moves & Health Shocks: News Roundup (Aug 18–19, 2025)

Genentech is ending its $2 billion cell therapy partnership with Adaptive Biotechnologies, citing cost-cutting but no safety issues. Kriya Therapeutics raised $313 million in Series D funding, one of the year’s largest biotech rounds. The FDA delayed Neurizon’s ALS drug trial review until October due to staffing shortages. Stealth BioTherapeutics has resubmitted its elamipretide application for Barth syndrome after two FDA rejections.
19 August 2025
····
Go toTop